Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SKP2 | Q13309 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | CCR8 | P51685 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.41 |
| ▸ | RELA | Q04206 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1146845 | 0.98 | SKP2 (0.43) | SKP2NPC1RAB9AMAPK1HPGD | |
| SCHEMBL8738529 | 0.93 | NPC1 (0.43) | SKP2NPC1RAB9AMAPK1HPGD | |
| SCHEMBL29191290 | 0.93 | SKP2 (0.40) | SKP2NPC1RAB9AMAPK1HPGD | |
| SCHEMBL11798255 | 0.92 | TDP1 (0.46) | NPC1RAB9AHPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL7963811 | 0.92 | TDP1 (0.46) | NPC1RAB9AHPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL1446914 | 0.92 | TDP1 (0.46) | NPC1RAB9AHPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL31004368 | 0.92 | TDP1 (0.46) | NPC1RAB9AHPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL913250 | 0.92 | TDP1 (0.46) | NPC1RAB9AHPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL7964430 | 0.92 | TDP1 (0.46) | NPC1RAB9AHPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL529596 | 0.92 | TDP1 (0.46) | NPC1RAB9AHPGDSMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118225742-A | Dissolved oxygen sensor and application thereof | 湖南大学 | 2024-06-21 | — | — | CN | claimed |
| CN-115109009-A | Synthesis method of 2-sulfonyl benzothiazole compound | 东华理工大学 | 2022-09-27 | — | — | CN | claimed |
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | MAZE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| CN-115109009-B | Synthesis method of 2-sulfonyl benzothiazole compound | 东华理工大学 | 2023-10-31 | — | — | CN | disclosed |
| CN-114605237-B | Preparation method and application of fluoroalkyl ketone compound | 武汉大学 | 2023-02-24 | — | — | CN | disclosed |
| CN-115109009-A | Synthesis method of 2-sulfonyl benzothiazole compound | 东华理工大学 | 2022-09-27 | — | — | CN | disclosed |
| US-20220259240-A1 | PROCESS FOR THE PREPARATION OF RUTHENIUM COMPLEXES | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2022-08-18 | — | — | US | disclosed |
| US-10858334-B2 | Method for aerobic oxidative coupling of thiophenes with a ligand-supported palladium catalyst | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2020-12-08 | — | — | US | disclosed |
| US-10793504-B2 | Methods for cross coupling | RECURIUM IP HOLDINGS, LLC (US) | 2020-10-06 | — | — | US | disclosed |
| US-20190210993-A1 | Method for Aerobic Oxidative Coupling of Thiophenes with a Ligand-Supported Palladium Catalyst | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-07-11 | — | — | US | disclosed |
| US-20190202769-A1 | METHODS FOR CROSS COUPLING | RECURIUM IP HOLDINGS, LLC | 2019-07-04 | — | — | US | disclosed |
| CN-107074850-A | Noval chemical compound | 葛兰素史密斯克莱知识产权发展有限公司 | 2017-08-18 | — | — | CN | disclosed |
| WO-2017061581-A1 | METHOD FOR SYNTHESIZING BIPYRIDINE COMPOUND AND METHOD FOR MANUFACTURING PYRIDINE COMPOUND | 株式会社神鋼環境ソリューション | 2017-04-13 | — | — | WO | disclosed |
| US-8357800-B2 | Bipyridine metal complexes for use as light-emitting material | SOLVAY (SOCIETE ANONYME) (BE) | 2013-01-22 | — | — | US | disclosed |
| US-8097361-B2 | Nanotube wiring | DOW GLOBAL TECHNOLOGIES LLC (US) | 2012-01-17 | — | — | US | disclosed |
| US-20100174078-A1 | Bipyridine metal complexes for use as light-emitting material | SOLVAY (SOCIETE ANONYME) (BE) | 2010-07-08 | — | — | US | disclosed |
| US-20100068621-A1 | NANOTUBE WIRING | DOW GLOBAL TECHNOLOGIES LLC | 2010-03-18 | — | — | US | disclosed |
| US-20090123837-A1 | Lithium rechargeable electrochemical cell | HPL (HIGH POWER LITHIUM) SA (CH) | 2009-05-14 | — | — | US | disclosed |
| US-7361414-B2 | Light emitting device and display apparatus using same | CANON KABUSHIKI KAISHA (JP) | 2008-04-22 | — | — | US | disclosed |
| EP-0411935-A2 | Copper radio sensitizers | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 1991-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858334-B2 | Method for aerobic oxidative coupling of thiophenes with a ligand-supported palladium catalyst | PPOX, TST, COX6C | SKP2 2061/4885NPC1 4792/4885RAB9A 3699/4885 |
| US-20190202769-A1 | METHODS FOR CROSS COUPLING | F2, C5, C9 | SKP2 1580/4885NPC1 2632/4885RAB9A 1446/4885 |
| US-20190210993-A1 | Method for Aerobic Oxidative Coupling of Thiophenes with a Ligand-Supported Palladium Catalyst | PPOX, TST, COX6C | SKP2 2061/4885NPC1 4792/4885RAB9A 3699/4885 |
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | APOL1, APOB, LDLR | SKP2 2536/4885NPC1 208/4885RAB9A 2263/4885 |
| US-20220259240-A1 | PROCESS FOR THE PREPARATION OF RUTHENIUM COMPLEXES | RUVBL1, RUVBL2, RPP30 | SKP2 2655/4885NPC1 4724/4885RAB9A 579/4885 |
| US-10793504-B2 | Methods for cross coupling | F2, C5, C9 | SKP2 1580/4885NPC1 2632/4885RAB9A 1446/4885 |
| US-20100174078-A1 | Bipyridine metal complexes for use as light-emitting material | OCIAD2, AP2M1, OCIAD1 | SKP2 187/4885NPC1 2306/4885RAB9A 931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.